WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY
A trial fibrillation is the most common cardiac source of systemic emboli and car-a significant reduction or even blockage of dioembolic stroke. Anticoagulants are recommended for preventing stroke in patients with non-valvular atrial fibrillation. Warfarin reduces the risk of stroke in patients w...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«REMEDIUM GROUP» Ltd.
2016-07-01
|
| Series: | Атеротромбоз |
| Subjects: | |
| Online Access: | https://www.aterotromboz.ru/jour/article/view/80 |
| _version_ | 1797883931370979328 |
|---|---|
| author | N. A. Novikova A. N. Volovchenko |
| author_facet | N. A. Novikova A. N. Volovchenko |
| author_sort | N. A. Novikova |
| collection | DOAJ |
| description | A trial fibrillation is the most common cardiac source of systemic emboli and car-a significant reduction or even blockage of dioembolic stroke. Anticoagulants are recommended for preventing stroke in patients with non-valvular atrial fibrillation. Warfarin reduces the risk of stroke in patients with AF by approximately two-thirds. New oral anticoagulants are becoming more common in recent years. Despite this, a number of clinical situations remain where the only possible anticoagulant is warfarin. |
| first_indexed | 2024-04-10T03:59:40Z |
| format | Article |
| id | doaj.art-a02756de94964c0a9650bb5ddd338c46 |
| institution | Directory Open Access Journal |
| issn | 2307-1109 2658-5952 |
| language | Russian |
| last_indexed | 2024-04-10T03:59:40Z |
| publishDate | 2016-07-01 |
| publisher | «REMEDIUM GROUP» Ltd. |
| record_format | Article |
| series | Атеротромбоз |
| spelling | doaj.art-a02756de94964c0a9650bb5ddd338c462023-03-13T07:10:42Zrus«REMEDIUM GROUP» Ltd.Атеротромбоз2307-11092658-59522016-07-0101505810.21518/2307-1109-2016-1-50-5876WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAYN. A. Novikova0A. N. Volovchenko1Первый Московский государственный медицинский университет им. И.М. Сеченова, МоскваI.M. Sechenov First Moscow State Medical UniversityA trial fibrillation is the most common cardiac source of systemic emboli and car-a significant reduction or even blockage of dioembolic stroke. Anticoagulants are recommended for preventing stroke in patients with non-valvular atrial fibrillation. Warfarin reduces the risk of stroke in patients with AF by approximately two-thirds. New oral anticoagulants are becoming more common in recent years. Despite this, a number of clinical situations remain where the only possible anticoagulant is warfarin.https://www.aterotromboz.ru/jour/article/view/80фибрилляция предсердийварфариндабигатранривароксабанапиксабаншкала same-tt2r2 |
| spellingShingle | N. A. Novikova A. N. Volovchenko WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY Атеротромбоз фибрилляция предсердий варфарин дабигатран ривароксабан апиксабан шкала same-tt2r2 |
| title | WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY |
| title_full | WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY |
| title_fullStr | WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY |
| title_full_unstemmed | WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY |
| title_short | WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY |
| title_sort | warfarin place in the anticoagulant therapy today |
| topic | фибрилляция предсердий варфарин дабигатран ривароксабан апиксабан шкала same-tt2r2 |
| url | https://www.aterotromboz.ru/jour/article/view/80 |
| work_keys_str_mv | AT nanovikova warfarinplaceintheanticoagulanttherapytoday AT anvolovchenko warfarinplaceintheanticoagulanttherapytoday |